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ABSTRACT
Background: Estimation of the number of people
in need of antiretroviral therapy (ART) in resource-limited
settings requires information on the time from
seroconversion to ART eligibility and from ART eligibility
to death.
Objectives: To estimate duration from seroconversion to
different ART eligibility criteria and from ART eligibility to
death in HIV-infected adults in low-income and middle-
income countries.
Methods: Participants with documented seroconversion
from five cohorts (two cohorts from Uganda, two from
Thailand and one from Co ˆte d’Ivoire) were analysed. We
used Weibull survival models and Bayesian simulation
methods to model true (unobserved) first time of
treatment eligibility. We set a consistency constraint so
that the mean duration from seroconversion to death was
equal to the mean from seroconversion to ART eligibility
plus the mean from eligibility to death.
Results: We analysed data from 2072 participants,
16 157 person-years of follow-up and 794 deaths. For the
criterion CD4 T-lymphocyte count ,200 cells 610
6/l, the
median duration from seroconversion to ART eligibility
was 6.1 years (95% credibility interval 3.3–10.4) for all
studies and 7.6 years (95% credibility interval 3.4–15.2)
for all but the Thai cohorts. Corresponding estimates for
the time from CD4 T-lymphocyte count ,200 cells610
6/l
to death were 2.1 years (0.7–4.8) and 2.7 years (0.8–
8.4). When including all cohorts, the mean time from
serconversion to CD4 T-lymphocyte count ,200 cells
610
6/l and from CD4 T-lymphocyte count ,200 cells
610
6/l to death represented 66% (38–87%) and 34%
(13–62%), respectively of the total survival time.
Conclusions: The duration of different ART eligibility
criteria to death was longer than the estimates used in
previous calculations of the number of people needing
ART. However, uncertainty in estimates was considerable
and heterogeneity across cohorts important.
The scale-up of antiretroviral therapy (ART)
represents an unprecedented effort to provide
access to life-saving drugs to HIV-infected patients
in resource-limited settings. The World Health
Organization estimates that as a result two million
people living with HIV/AIDS in low-income and
middle-income countries were receiving treatment
at the end of in 2006.
1 An important question is the
coverage of ART in these settings; in other words,
what proportion of patients in need of ART is
receiving it, and how far away from reaching the
goal of universal access are we?
To estimate coverage of ART, information about
the untreated natural history of HIV infection in
low-income and middle-income countries is
needed, especially on the duration from infection
(seroconversion) to the point in time when an
individual becomes eligible for ART, and from ART
eligibility to death.
23Criteria for treatment elig-
ibility differ between settings and guidelines. For
example, the current International AIDS Society-
USA guidelines for treatment of HIV infection in
adults
4 recommend that ART should be considered
in asymptomatic patients after the CD4 count falls
below 350 cells 610
6/l and before it declines to 200
cells610
6/l. In contrast, the 2002 WHO guidelines,
which are still used in some countries—for
example, in South Africa, recommend ART only
for patients with WHO stage 4 disease or a CD4
cell count of less than 200 cells 610
6/l.
5 These
recommendations were revised in 2003 and now
state that, in addition, treatment should also be
started in patients with WHO stage 3 and a CD4
count between 200 and 350 cells 610
6/l.
6
Few seroconverter cohorts exist in low-income
and middle-income countries, and the number of
participants enrolled is relatively small.
Collaborative analyses of individual participant
data from several studies are useful in this
situation.
7 Recently, Todd and colleagues
8 esti-
mated time from seroconversion to death in a
collaborative analysis of eight seroconverter
cohorts from low-income and middle-income
countries before ART became available; however,
their study did not address time to ART eligibility.
We established the eligibility for Antiretroviral
Therapy in lower income countries (eART-linc)
collaboration with the aim to estimate time from
seroconversion to ART eligibility and from ART
eligibility to death in HIV-infected adults from
lower-income countries.
METHODS
Cohort studies
We contacted cohort studies from low-income and
middle-income countries of HIV-infected adults
with documented last negative and first positive
HIV tests and information on the evolution of
CD4 counts or clinical stage, and invited them to
contribute data to the eART-linc collaboration.
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in detail elsewhere,
9–13 participated in the current analyses
(table 1): the Primo-CI ANRS 1220 cohort
9 in Abidjan, Co ˆte
d’Ivoire; the Rakai District cohort
10 in rural Uganda; the Masaka
District cohort,
11 also in rural Uganda; the Royal Thai Army
conscripts cohort
12 in Thailand and the blood donors cohort
13 in
Chiang Mai, Thailand. Inspection of the data received showed
that the information on CD4 count evolution was limited for
the Thai cohorts,
12 13 and these therefore contributed to
estimation of the time from seroconversion to death only.
Also, information on clinical stage was available only for the
Masaka cohort.
11
Observable and unobservable information
Figure 1 shows the observable information and the time points
and intervals we set out to estimate. The exact date of reaching
treatment eligibility cannot be observed because the relevant
criteria, including CD4 counts and clinical stage, are assessed at
certain points in time only. Individuals for whom treatment
eligibility was observed had two dates: the last date with
available information before eligibility was observed and the
first date at which available information indicated that ART
eligibility had been reached. The true date of treatment
eligibility will lie somewhere between these two dates.
Statistical analyses
We used Weibull survival models
14 to estimate the duration
from seroconversion to various eligibility criteria for ART, from
ART eligibility to death or from serconversion to death. The
date of seroconversion was calculated as the midpoint between
the last documented negative HIV test and the first documen-
ted positive HIV test. Follow-up was censored on the date the
patient was last known to be alive. In patients who initiated
ART, follow-up was censored on the date of starting therapy.
We did analyses for various CD4 thresholds (,200 cells 610
6/l,
,275 cells 610
6/l, ,350 cells 610
6/l) and for the combined
criteria WHO clinical stage 3 and CD4 ,350 cells 610
6/l. In
additional multivariable analyses we included gender and age.
HIV subtype could not be included because subtype was highly
correlated with the country in which the cohort was conducted.
For descriptive purposes, we calculated and plotted Kaplan-
Meier cumulative incidence estimates for some outcomes for
each cohort.
We accounted for differences in survival distributions
between cohorts using the hierarchical random effects model
assuming proportional hazards. The random effects were
assumed to be normally distributed around a common mean.
We allowed for two different Weibull distributions, one each for
the duration from seroconversion to treatment eligibility and
from treatment eligibility to death. For the Thai cohorts, which
did not contribute information on treatment eligibility, we
modelled the duration from seroconversion to death using a
third Weibull distribution. We set a consistency constraint on
the mean survival times such that the mean duration from
seroconversion to death was equal to the sum of the mean
duration from seroconversion to the estimated time of ART
eligibility and the mean duration from ART eligibility to death.
In an additional analysis we excluded the Thai cohorts.
Estimation of time periods was based on a fully probabilistic
approach using simulation methods. Vague prior distribu-
tions for parameters of interest were specified by using normal
distributions with variances equal to 10
3. Samples from the
posterior distributions for quantities of interest were
obtained by Markov Chain Monte Carlo simulations based on
100 000 iterations from which the first 60 000 iterations
were discarded. The influence of age at seroconversion and sex
on survival was explored in standard proportional hazard
Weibull regression models. Age was entered as a continuous
variable.
All analyses were performed using Stata (version 9.2, College
Station, TX, USA) and WinBUGS
15 (version 1.4.1, Cambridge,
UK). Results are presented as means and medians with 95%
credibility intervals (CrI) or as conventional 95% confidence
intervals (CI). In Bayesian statistics credibility intervals are
commonly used to provide summary information about the
probability distribution of a parameter of interest. Similar to
95% confidence intervals, they cover a range in which the true
value of the unknown quantity lies with 95% probability.
Table 1 Characteristics of cohorts and participants included in analyses
Cohort
Combined
Co ˆte d’Ivoire
(Abidjan) Uganda (Masaka) Uganda (Rakai)
Thailand (Royal
Thai Army) Thailand (Chiang Mai)
Reference Minga et al
9 Morgan et al
32 Wawer et al
33 Rangsin et al
12 Nagachinta et al
13 –
Study population Blood donors Participants in
community cohort
Participants in
community cohort
Military
conscripts
Male blood donors and
their female partners
–
Year of start of study 1997 1990 1991 1998 1992
No of participants included in
analyses (%)
253 (100) 338 (100) 411 (100) 233 (100) 837 (100) 2072 (100)
Median (IQR) interval between
last negative and first positive
HIV-1 test, months
7.5 (3.4–19.1) 12.5 (11.7–24.3) 22.4 (14.6–37.7) 8.5 (5.7–9.5) 50.7 (31.6–69.8) 24.0 (11.8–50.1)
No of women (%) 97 (38.3) 180 (53.2) 256 (62.3) 0 (0) 267 (31.9) 800 (38.6)
No of patients starting ART (%) 79 (31.2) 57 (16.9) 151 (36.7) 0 (0) 0 (0) 287 (13.8)
Mean (SD) age at baseline,
years
29.1 (7.1) 32.0 (13.6) 35.8 (2.5) 22.1 (0.9) 28.7 (6.4) 29.9 (8.3)
Median (IQR) baseline CD4 cell
count (IQR), cells 610
6/l
472 (331–648) 553 (425–743) 409 (235–584) NA NA –
Median (IQR) number of CD4
counts per person
9 (5–14) 5 (2–11) 3 (2–7) NA NA –
Median (IQR) follow up from
seroconversion, years
5.4 (5.4–7.6) 4.9 (3.3–7.8) 5.7 (3.8–7.6) 6.0 (5.3–6.7) 6.5 (5.2–9.1) 6.0 (4.4–7.8)
NA, not systematically assessed and therefore not analysed in this study; SD, standard deviation; IQR, interquartile range.
The baseline CD4 count relates to the first measurement after seroconversion.
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A total of 2072 adults with documented seroconversion were
included in the analyses (table 1). In the African cohorts the
follow-up of 294 patients (14.2%) was censored because ART
was started. In total, 794 (38.3%) patients died, most of them
(762, 96.0%) while not on ART. Figure 2 shows the cumulative
incidences from seroconversion to death or to first time ART
eligibility was observed for different eligibility criteria. For time
to ART eligibility the figure also includes the fitted curves based
on the median of the posterior distribution of the common
mean of the Weibull parameters. Owing to the difference
between the true (but unobservable) time of reaching ART
eligibility for the first time, and the first time eligibility was
observed, the fitted curves are generally above the observed
curves.
Table 2 shows the estimated mean and median years from
seroconversion to different ART eligibility criteria and from
ART eligibility to death. Means were 1–2 years higher than
medians and ranged from 7.6 years from seroconversion to a
CD4 count ,200 cells 610
6/l to 3.9 years for the period from
reaching a CD4 count ,200 cells 610
6/l to death.
Corresponding medians were 6.1 years and 2.1 years. For most
estimates 95% credibility intervals were fairly wide. The
additional analysis excluding the Thai cohorts resulted in
intervals that were 0.5 to 1.6 years longer for medians and 0.8
to 2.1 years longer for means, with substantially wider
confidence intervals. For the CD4 criteria, the sum of the mean
duration from seroconversion to eligibility and the mean
duration from eligibility to death gave mean durations from
seroconversion to death of 11.3–11.7 years, depending on the
eligibility criterion (table 2). Excluding the Thai cohorts resulted
in longer periods, with a sum of the means of the two periods
ranging from 13.7 years to 14.6 years (table 2). The sum of the
means for the combined CD4 and clinical stage criterion, which
was estimated using the Masaka cohort data only, was 10.9
years. Note that the medians shown in table 2 cannot simply be
added to obtain the median duration from seroconversion to
death, only the means add up in this way. To increase
applicability to different settings, table 2 also gives time
intervals expressed as the percentage of the total time from
seroconversion to death.
Heterogeneity of model parameters across cohorts was
important. The mean of the random effects standard devia-
tion ranged from 0.8 to 0.92 with lower credibility bounds
above 0.4. When including age and sex in the models, estimates
of survival were reduced for older people, with hazard ratios
ranging from 1.02 to 1.03 per year increase in age with lower
bounds of the 95% credibility intervals 1.01 and upper bounds
not exceeding 1.05. Analyses comparing women with men gave
hazard ratios ranging from 0.91 to 1.09 with wide 95%
credibility intervals that always included 1: lower 95%
credibility bounds ranged from 0.62 to 0.71, higher bounds
from 1.4 to 1.7.
Figure 1 Schematic representation of observed and estimated time
points and intervals in the natural history of HIV infection.
Figure 2 Kaplan-Meier plots of the
cumulative probability of death and of
reaching different eligibility criteria for
antiretroviral therapy.
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The eART-linc collaboration, which currently includes over
2000 untreated adults from lower-income settings with
documented seroconversion, made analyses of individual
participant data to estimate the periods from seroconversion
to different ART eligibility criteria, and from ART eligibility to
death possible.
The collaborative analysis of individual participant data is an
important strength of this study: meta-analyses that use
individual participant data are considered the gold standard
and yardstick for meta-analyses and systematic reviews.
16
Indeed, in previous reviews of published studies
17 18 we found
that the type of data presented in articles was very hetero-
geneous, confirming earlier observations on common difficulties
with systematic reviews of prognostic
19 and other observational
studies. This approach is also used by the Alpha Network
(Analysing Longitudinal Population-based HIV/Aids data on
Africa) to analyse patterns of mortality in HIV-infected adults,
based on pooled data from several community-based cohort
studies.
82 02 1
The exact date of reaching treatment eligibility can usually
not be observed because the relevant criteria, including CD4
counts and clinical stage, are not assessed continuously. One
approach to this problem is to take the first date eligibility
criteria are met, which may provide a good approximation if the
relevant information is collected regularly and frequently.
However, this is problematic in the more common situation
when intervals between measurements are relatively wide,
leading to underestimation of the duration from true ART
eligibility to death. In clinical decision-making the date the
criteria for ART are documented for the first time is the
important date and should lead to the initiation of ART. Of
note, many patients in lower-income countries start ART late or
very late, with CD4 cell counts well below 200 cells 610
6/l.
22–24
However, when estimating the need at the population level, it is
the actual date of having reached ART eligibility for the first
time that is of interest. In the present analysis we chose an
analytical strategy that took into account that only interval
information on ART eligibility was available from cohorts.
Unsurprisingly, our estimates are higher than published
estimates, which took the date when eligibility was documen-
ted for the first time as the point of departure. For example, we
estimated the median duration from a CD4 count ,200 cells
610
6/l to death as 2.1 years (2.7 years when excluding the two
cohorts from Thailand) and the mean as 3.9 years (5.2 years
when excluding the two cohorts from Thailand). Previously
published estimates in untreated patients range from 7 months
to 22 months (table 3). The distribution of survival times is
skewed, which explains that estimates for the mean were higher
than those for medians.
Mortality patterns after seroconversion have been previously
described for several of the seroconverter cohorts included in
this analysis.
8 20 25–29 Interestingly, mortality was similar across
cohorts, particularly in the first years after seroconversion,
Table 2 Estimated time from seroconversion to different ART eligibility criteria and from ART eligibility to death
Time interval
ART eligibility criteria
,200 CD4 cells 610
6/l ,275 CD4 cells 610
6/l ,350 CD4 cells 610
6/l
,350 CD4 cells 610
6/l and
WHO stage 3
All cohorts
Seroconversion to eligibility (years)
Median (95% CrI) 6.1 (3.3–10.4) 4.2 (1.9–7.9) 2.7 (0.9–6.3) 5.6 (5.0–6.2)
Mean (95% CrI) 7.6 (4.1–12.9) 5.4 (2.5–10.3) 4.0 (1.4–9.2) 6.4 (5.8–7.1)
Percentage* 66 (38–87) 48 (23–75) 34 (12–64) 58 (50–65)
Eligibility to death (years)
Median (95% CrI) 2.1 (0.7–4.8) 4.0 (1.7–8.0) 6.0 (2.9–11.7) 3.0 (2.4–3.8)
Mean (95% CrI) 3.9 (1.4–9.1) 5.9 (2.5–11.7) 7.7 (3.8–15.0) 4.5 (3.5–6.4)
Percentage* 34 (13–62) 52 (25–78) 66 (36–88) 42 (35–50)
Excluding the two Thai cohorts
Seroconversion to eligibility (years)
Median (95% CrI) 7.6 (3.4–15.2) 4.8 (1.9–11.6) 3.2 (1.0–9.7) 5.6 (5.1–6.2)
Mean (95% CrI) 9.4 (4.3–19.2) 6.3 (2.4–15.1) 4.8 (1.5–14.4) 6.4 (5.8–7.1)
Eligibility to death (years)
Median (95% CrI) 2.7 (0.8–8.4) 5.0 (1.6–13.8) 7.6 (3.0–18.3) 3.0 (2.4–3.8)
Mean (95% CrI) 5.2 (1.5–15.9) 7.4 (2.5–20.5) 9.8 (3.8–23.7) 4.5 (3.5–6.4)
*Percentage of duration from seroconversion to death.
CrI, credibility interval.
Table 3 Published estimates of survival from CD lymphocyte counts ,200 CD4 cells 610
6/l
Study, year of publication No Country Years
Median months of survival
(95% CI)
Lawn, 2005
34 134 South Africa 2002–5 20 (14 to 28)
Costello, 2005
35 167 Thailand 1993–9 21.6 (19 to 24)*
Badri, 2004
36 447 South Africa 1992–2001 23.6 (21 to 27)
Schim van der Loeff, 2002
37 378 The Gambia 1986–97 7 (5 to 9)
Kilmarx, 2000
38 15 Thailand 1991–8 11 (7 to 15)
French, 1999
39 78 Uganda before 1998 9 (7 to 15)
Van der Paal, 2007
28 147 Uganda 1990–2003 25.7 (21 to 31)
*Men only.
CI, confidence interval.
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cohort from Co ˆte d’Ivoire, which showed lower cumulative
mortality than the other four cohorts, despite similar prob-
abilities of observing CD4 criteria for ART eligibility. The lower
mortality and morbidity might be explained by under-ascertain-
ment of deaths in this clinic-based cohort or by the early
introduction of cotrimoxazole prophylaxis, in 1994, by the
Centre National de Transfusion Sanguine in Abidjan.
9 Indeed,
two clinical trials from Co ˆte d’Ivoire and one from Senegal
showed a substantial reduction of mortality: the combined
relative risk was 0.69 (95% confidence interval 0.55 to 0.87).
30
About five years after seroconversion mortality was higher in
the Thai studies and, particularly, in the Chiang Mai blood
donor cohort.
13 The inclusion of paid blood donors of lower
socioeconomic strata might explain the higher mortality in this
cohort. There is debate on whether HIV subtype (predomi-
nantly subtype E in Thailand) influences survival.
8 The
additional analysis excluding the Thai studies therefore resulted
in longer duration estimates. In addition to reporting time
intervals in years, we therefore also expressed intervals as the
percentage of the total time from seroconversion to death. This
should facilitate the application of results to populations with
different background and HIV-related mortality. We found that
depending on the ART eligibility criteria considered, 34% to
66% of the mean duration from seroconversion to death occurs
after having become eligible for ART.
Our analysis has several limitations. The number of included
cohorts and the number of seroconverters was small and
information on treatment eligibility was available for only three
of the five cohorts. We used a simple midpoint approximation
to estimate the date of seroconversion, despite the fact that in
some cohorts intervals between tests were long. Estimation of
model parameters became difficult when allowing uncertainty
about the date of seroconversion as well as the time of reaching
ART eligibility. Also, midpoint approximation is common
practice in analyses of survival time from seroconversion to
death. We analysed all-cause mortality and could not distin-
guish between HIV-associated mortality and other causes of
death. We used parametric survival models and thus made
assumptions about the shape of the survival distributions that
may not always be appropriate.
In conclusion, estimation of the number of people in need of
ART in resource-limited settings should be based on figures for
survival from ART eligibility to death that are somewhat higher
than those used previously,
2 and support the recent updates to
the Joint United Nations Programme on HIV/AIDS (UNAIDS)
Spectrum projection software.
31 Finally, we would welcome
additional studies in the eART-linc collaboration in order to
obtain more precise and more widely applicable estimates in
future analyses. Interested investigators are invited to contact
us at eART-linc@ispm.unibe.ch.
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